These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35031785)

  • 1. A non-invasive approach for NEPC diagnosis.
    Masone MC
    Nat Rev Urol; 2022 Feb; 19(2):67. PubMed ID: 35031785
    [No Abstract]   [Full Text] [Related]  

  • 2. Platinum sensitivity in metastatic prostate cancer: does histology matter?
    Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.
    Wang HT; Yao YH; Li BG; Tang Y; Chang JW; Zhang J
    J Clin Oncol; 2014 Oct; 32(30):3383-90. PubMed ID: 25225419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients.
    Bhagirath D; Liston M; Akoto T; Lui B; Bensing BA; Sharma A; Saini S
    Sci Rep; 2021 Apr; 11(1):8279. PubMed ID: 33859239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SRRM4 gene expression correlates with neuroendocrine prostate cancer.
    Li Y; Zhang Q; Lovnicki J; Chen R; Fazli L; Wang Y; Gleave M; Huang J; Dong X
    Prostate; 2019 Jan; 79(1):96-104. PubMed ID: 30155992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer.
    Lin D; Dong X; Wang K; Wyatt AW; Crea F; Xue H; Wang Y; Wu R; Bell RH; Haegert A; Brahmbhatt S; Hurtado-Coll A; Gout PW; Fazli L; Gleave ME; Collins CC; Wang Y
    Oncotarget; 2015 Jan; 6(3):1806-20. PubMed ID: 25544761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
    Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
    Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
    Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo.
    Baek DS; Kim YJ; Vergara S; Conard A; Adams C; Calero G; Ishima R; Mellors JW; Dimitrov DS
    Cancer Lett; 2022 Jan; 525():97-107. PubMed ID: 34740610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
    Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
    J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Aggressive variants of castration resistant prostate cancer (CRPC): neuroendocrine prostate cancer.].
    Quicios-Dorado C; Bolufer-Moragues E; Gomis-Goti C; Cabello-Benavente R; Cannata-Ortiz PJ; González-Enguita C
    Arch Esp Urol; 2018 Sep; 71(8):721-734. PubMed ID: 30319132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
    Mosquera JM; Beltran H; Park K; MacDonald TY; Robinson BD; Tagawa ST; Perner S; Bismar TA; Erbersdobler A; Dhir R; Nelson JB; Nanus DM; Rubin MA
    Neoplasia; 2013 Jan; 15(1):1-10. PubMed ID: 23358695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
    Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.
    Yao J; Liu Y; Liang X; Shao J; Zhang Y; Yang J; Zheng M
    Front Endocrinol (Lausanne); 2021; 12():778758. PubMed ID: 34956090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic modulations and lineage plasticity in advanced prostate cancer.
    Ge R; Wang Z; Montironi R; Jiang Z; Cheng M; Santoni M; Huang K; Massari F; Lu X; Cimadamore A; Lopez-Beltran A; Cheng L
    Ann Oncol; 2020 Apr; 31(4):470-479. PubMed ID: 32139297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.